Year-End Report Publication Postponed
The Board of Directors of SciBase Holding AB (publ) has decided to reschedule the release of the year-end report for the financial year 2025. The new date set for this significant announcement is March 13, 2026. This adjustment aligns the trading restriction period with the subscription phase of an ongoing rights issue.
Reasons for the Postponement
The decision to postpone the publication is strategically made to ensure that the financial disclosures are aligned with the needs of the company and its investors. This approach demonstrates SciBase's commitment to transparency and effective communication with its shareholders. By synchronizing the reporting timeline with major corporate actions like rights issues, SciBase positions itself to provide valuable insights and updates promptly.
Insights from the Company Leadership
Jesper Høiland, Chairman of the Board at SciBase, emphasizes the importance of timely information for stakeholders, stating that the move to delay the report allows for a more comprehensive outlook on the company's financial health and operational progress. Similarly, CFO Michael Colérus shares that this timing will ensure that investors receive a complete picture of the company's developments in relation to their rights issue.
About SciBase and Its Innovations
SciBase is a pioneering global medical technology company focused on dermatology. The company specializes in early detection and prevention through its flagship product, Nevisense, an advanced point-of-care platform that utilizes artificial intelligence and innovative electrical impedance spectroscopy (EIS) technology. These groundbreaking features enhance diagnostic accuracy, fostering proactive skin health management.
The mission of SciBase revolves around reducing patient suffering and improving clinician capabilities. With a commitment to timely detection and intervention, the company aims to save lives and mitigate healthcare costs. This dedication to advancing medical technology is bolstered by over 20 years of research at the prestigious Karolinska Institute in Stockholm, Sweden.
SciBase has been an active participant in the Nasdaq First North Growth Market since June 2, 2015, consistently striving to lead advancements in dermatological care.
Continuing Engagement With Stakeholders
The company encourages ongoing dialogue with its shareholders and the public. Stakeholders can follow SciBase for updates about earnings reports, innovative product releases, and other significant developments. Regular communication ensures that everyone involved with SciBase can make informed decisions based on the company's activities and market position.
Contact Information
For further inquiries regarding the postponement or any other concerns, please reach out to:
Jesper Høiland, Chairman of the Board – phone +45 612 207 30
Michael Colérus, Chief Financial Officer – phone +46 70 341 34 72
Interest in the company's developments can also be guided through its Certified Adviser, DNB Carnegie Investment Bank AB (publ), who is available at +46 8 588 68 570.
Frequently Asked Questions
Why has SciBase postponed its year-end report?
The postponement allows SciBase to align the trading restriction period with its ongoing rights issue to provide stakeholders with a comprehensive view of the company's financial position.
When is the new publication date for the year-end report?
The year-end report for the financial year 2025 will now be published on March 13, 2026.
What is SciBase's focus in the medical technology field?
SciBase specializes in dermatology, particularly in early detection and prevention through its innovative product, Nevisense.
How can stakeholders stay informed about SciBase?
SciBase encourages stakeholders to remain engaged through regular updates on its financial performance and innovations in dermatological technology.
Who can be contacted for more information about SciBase?
For inquiries, stakeholders can contact Jesper Høiland or Michael Colérus, who are responsible for guiding information regarding the company's operations.
